Skip to content
  • Media
  • Investors
  • Media
  • Investors
  • TAMP Therapy Platform
    • Our Science
    • RenovoCath®
  • Physicians
    • Evidence
    • Resources
  • Patients
    • The Procedure
    • FAQs
    • Patient Stories
    • Physician Locator
  • About Us
    • Overview & Leadership
    • Board of Directors
    • Advisory Boards
  • Contact
  • Media
  • Investors
  • TAMP Therapy Platform
    • Our Science
    • RenovoCath®
  • Physicians
    • Evidence
    • Resources
  • Patients
    • The Procedure
    • FAQs
    • Patient Stories
    • Physician Locator
  • About Us
    • Overview & Leadership
    • Board of Directors
    • Advisory Boards
  • Contact
  • Media
  • Investors

Day: April 27, 2023

RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors

RenovoRx appoints Robert J. Spiegel to Board of Directors

RenovoRx announced today that Robert J. Spiegel, MD, has been appointed to the Company’s Board of Directors, effective April 25, 2023.

RenovoCath is FDA-cleared for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial conducted under an IND.

Facebook-f X-twitter Linkedin-in Youtube

Menu

  • TAMP Therapy Platform
  • Our Science
  • RenovoCath®
  • Physicians
  • Evidence
  • Clinical Trials
  • Patients
  • The Procedure
  • FAQs
  • Patient Stories
  • Physician Locator
  • About
  • Leadership
  • Board of Directors
  • Advisory Boards
  • Contact
  • TAMP Therapy Platform
  • Our Science
  • RenovoCath®
  • Physicians
  • Evidence
  • Clinical Trials
  • Patients
  • The Procedure
  • FAQs
  • Patient Stories
  • Physician Locator
  • About
  • Leadership
  • Board of Directors
  • Advisory Boards
  • Contact
  • 2570 W. El Camino Real, Suite 640
    Mountain View, CA 94040
  • (650) 284-4433
  • info@renovorx.com
© 2026 RenovoRx®. All rights reserved.

Privacy Statement | Terms of Use